1	Individualized Hybrid Electroconvulsive Therapy (i-HECT) Shows Rapid Anti-Depressant
2	Effect and Improved Cognition in Young Patients with Depression
3	
4 5	Jing-ya Zhang ^a †, Lun Zeng ^a †, Jia Li ^b , Mian-mian Chen ^c , Shu-xian Xu ^c , Baijian Tan ^a , Xin-hui Xie ^{c,d} *
6	Affiliations:
7	a. Department of Clinical Psychology, Second People's Hospital of Huizhou, Huizhou, China.
8	b. Electroconvulsive Therapy Room, Second People's Hospital of Huizhou, Huizhou, China.
9	c. Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China.
10	d. Brain Function and Psychosomatic Medicine Institute, Second People's Hospital of Huizhou,
11	Huizhou, China.
12	
13	†These authors have contributed equally to this work.
14	
15	*Corresponding author: Xin-hui Xie
16	Addresses: 1) Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Jiefang Road,
17	Wuchang District, Wuhan, Hubei, PR China. 2) Brain Function and Psychosomatic Medicine Institute,
18	Second People's Hospital of Huizhou, Huizhou, China.
19	E-mail: xxh.med@gmail.com; xin-hui.xie@whu.edu.cn
20	
21	Conflict of Interest
22	The authors declare that there is no conflict of interest in this work.
23	
24 25	Funding This work was supported by grant from the Science and Technology Program of Huizhou (Grant No.
25 26	2021SC010311001 (Baijian Tan) and 2022CQ010013 (Lun Zeng)) and the Guangdong Medical
20	Research Foundation (Grant No.A2022333 (Lun Zeng)). This work has not received funding/assistance
28	from any commercial organizations. The funding source had no roles in the design of this study and
29	will not have any roles during the execution, analyses, interpretation of the data, or decision to submit
30	results.
31	
32	Authors' contributions
33	Jing-ya Zhang: Investigation, Data Curation, Writing - Original Draft; Lun Zeng: Investigation, Data
34	Curation, Writing - Original Draft, Funding acquisition; Jia Li: Investigation, Data Curation; Mian-mian
35	Chen: Visualization, Writing - Review & Editing; Shu-xian Xu: Writing - Review & Editing; Baijian
36	Tan: Supervision, Funding acquisition; Xin-hui Xie: Conceptualization, Methodology, Formal analysis,

- Writing Original Draft; Writing Review & Editing. 37
- 38

39 Highlights

- Designed a novel but simple ECT protocol, i-HECT, for young depression patients.
- The trial employed Simon's optimal two-stage design with a high power of 0.95.
- The i-HECT rapidly improved both depression symptoms and cognitive functions.

Abstract 43

- **Background:** For young patients with depression, electroconvulsive therapy (ECT) is highly effective 44
- but causes acute cognitive side effects. We designed a new i-HECT therapy combines ECT with low-45
- charge electrotherapy (LCE) and individual symptom monitoring to reduce cognitive impairments. 46
- 47 Methods: i-HECT comprised two treatments: ECT and LCE. ECT utilized an energy set of 1.5 times
- 48 the seizure threshold (ST), while LCE was set at 0.5 ST. The initial session employed ECT. Subsequent
- sessions involved ECT or LCE, depending on whether meeting the ECT-LCE transition criteria 49
- (MADRS total score < 22 or $\ge 50\%$ reduction), assessed after each session. 50
- **Results**: The intention-to-treat analysis revealed an 80.4% response rate and a 58.7% remission rate 51
- (Hedges' g = 3.29). Notably, both subjective and objective cognitive functions significantly improved 52 post-i-HECT treatments and during the 3-month follow-up periods. 53
- 54 **Conclusion:** The i-HECT protocol may provide a rapid antidepressant treatment option with cognitive
- 55 benefits for young depression patients.
- 56
- **Keywords**: Electroconvulsive Therapy; i-HECT; Hybrid-ECT; rapid antidepressant effect; cognition; 57
- 58 safety; side effect
- 59

1. Introduction 60

Severe depressive symptoms in young patients can result in significant consequences, underscoring the 61 critical need for prompt and efficacious antidepressant interventions. Although electroconvulsive 62 therapy (ECT) exhibits rapid antidepressant efficacy [1], young patients experience acute significant 63 64 memory and cognitive impairments as side effects [2].

65 During ECT treatment, symptom reduction is rapid initially, and side effects increase over time. To balance efficacy and side effects, we proposed a new ECT strategy termed Hybrid-ECT. In Hybrid-66 ECT, the first three sessions use standard bilateral ECT with energy set at 1.5 times the seizure threshold 67 (ST). Thereafter, it transitions to low-charge electrotherapy (LCE) at 0.5 ST. Our previous randomized 68 controlled trial (RCT) demonstrated that Hybrid-ECT maintained similar antidepressant effects to ECT 69 70 but with significantly fewer side effects [3].

71 Furthermore, after reviewing data from both Hybrid-ECTs and ECTs, we noted individual 72 variations in the initial response to ECTs. For instance, while some patients experienced a 50% decline 73 in depression scale scores after a single ECT session, others may require more than nine sessions to achieve similar results. The variability suggested the potential for personalized transition conditions 74 75 from ECT to LCE within Hybrid-ECT, aiming to optimize therapeutic benefits. Therefore, we devised 76 a new but simple protocol called individualized Hybrid-ECT (i-HECT). Under the i-HECT protocol, 77 we assess patients' symptoms after each ECT session. If the predetermined ECT-LCE transition criteria are met, we implement the switch. To evaluate the antidepressant efficacy and side effects, particularly 78

- 79 cognitive, of i-HECT in young patients with depression, we conducted this trial.
- 80

2. Methods 81

This single-arm trial employed a Simon's optimal two-stage design [4] with a 3-month follow-up 82

- duration, conducted at the Second People's Hospital of Huizhou (April 2021-November 2023) in 83
- 84 accordance with the Declaration of Helsinki [5]. Both patients and raters remained blinded to the ECT-
- LCE transition. The Human Ethics Committee of the Hospital approved the protocol. Patients and their 85
- 86 legal guardians can withdraw at any time for any reason. Trial Registration: Chinese Clinical Trial
- Registry (http://www.chictr.org.cn, ChiCTR2100045682). 87
- 88 **2.1 Patients**
- 89 Inclusion criteria: 1) Age 16–25 years old; 2) Inpatients diagnosed with unipolar or bipolar depression
- according to ICD-10, with or without psychotic symptoms; 3) Baseline Montgomery-Åsberg 90
- Depression Rating Scale (MADRS) [6] score ≥ 22 . 91
- Exclusion criteria: 1) Pregnancy; 2) Participation in other studies within 30 days; 3) Undergoing 92
- 93 of ECT or repetitive transcranial magnetic stimulation (rTMS) treatment within the past 6 months; 4)
- Previous poor response to ECT; 5) History of substance abuse disorder; 6) Presence of 94
- 95 contraindications to ECT or anesthesia risks; 7) History of epilepsy.

2.2 i-HECT procedures (Figure 1) 96

2.2.1 Basic settings 97

- The i-HECT protocol comprised two treatments: ECT (1.5 ST) and LCE (0.5 ST), consistent with our 98
- previous report [3]. ECT/LCE sessions (three times per week) were performed using a spECTRUM 99
- 5000Q ECT instrument (MECTA Corporation, OR, USA), with pulse width of 1 ms and a fixed 100
- 101 current of 800 mA. The dose titration procedure was performed to determine the ST during the first
- session. Subsequent treatments were either ECT or LCE based on whether the patient met the criteria 102
- for ECT-LCE transition. 103

medRxiv preprint doi: https://doi.org/10.1101/2024.08.01.24311339; this version posted August 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

2.2.2 Criteria for ECT-LCE transition 104

- When either of the following conditions is met, the next treatment is switched to LCE: a) MADRS total 105
- score < 22; b) MADRS total score reduction \geq 50%. 106
- **2.2.3** Criteria for terminating i-HECT treatment 107
- After meeting any of the following criteria, i-HECT treatment was terminated and transitioned to the 108
- follow-up period: a) Completion of 12 ECT/LCE sessions; b) MADRS total score \leq 12; c) A consecutive 109
- decrease of <2 points over three MADRS assessments; d) Other reasons, such as voluntary withdrawal 110
- or other medical considerations. 111

2.3 Visit Schedule 112

- The five visits were set at 1) baseline; 2) post-ECT-LCE-transition; 3) post-treatment (within 24-48 113
- hour after the last ECT/LCE session); 4) end of the 1-month follow-up period; and 5) end of the 3-114 month follow-up period. 115

116 2.4 Pharmacotherapy

Patients maintained their antidepressants and antipsychotics during the trial. Anticonvulsants, mood 117 stabilizers, or lithium were discontinued during the i-HECT treatment. Single dose of alprazolam or 118 oxazepam were prescribed as necessary when patients became agitated or felt anxious, but were 119 120 prohibited 24 hour before ECT/LCE sessions. When patients suffered from insomnia, zopiclone,

121 eszopiclone, or zolpidem were temporarily prescribed.

2.5 Statistical analysis 122

- The primary outcome is the response rate analyzed in the intent-to-treat sample. Response is defined as 123 a reduction of \geq 50% in MADRS total score relative to baseline at the post-treatment visit. Additionally, 124 achieving a MADRS score ≤ 12 is considered remission. 125
- The trial employed an optimal Simon's two-stage design [4], with a null threshold referencing 126 O'Reardon et al.'s RCT set at 18.1% [7], and an alternative threshold referencing Kellner et al.'s RCT 127 set at 43% [8]. In stage I, 19 patients will be recruited. If 4 or fewer responders are observed, the trial 128 will be halted prematurely. Otherwise, an additional 27 patients will be recruited in stage II. If 13 or 129 130 more responses among these total 46 patients, the null hypothesis will be rejected, indicating promise for the i-HECT treatment. The design controls the type I error rate at 0.05 and yields the power of 0.95. 131 132 The secondary outcomes including MADRS and its subscales, 9-item Patient Health Questionnaire 133 (PHQ-9) [9], Generalized Anxiety Disorder 7 (GAD-7) [10], Columbia–Suicide Severity Rating Scale (C-SSRS) [11], and Positive and Negative Syndrome Scale (PANSS) [12]. The subjective cognitive 134 functions were evaluated using Subjective Cognitive Decline Questionnaire, and the objective cognitive 135 functions were evaluated using Repeatable Battery for the Assessment of Neuropsychological Status 136 137 (RBANS) [13], and Stroop Color and Word Test [14]. Orientation recovery tests (ORTs) after each ECT/LCE session were used to measure recovery time after ECT/LCE. Any adverse events (AEs) or 138 drop-out for any reason was recorded to analyze the safety. The linear mixed model and the least square 139 mean (LSM) and its 95% confidence intervals (CIs) were used to estimate the effects of outcomes at 140
- each visit using the *LmerTest* package [15] in R (version 4.2.0). 141
- 142

3. Results 143

144 A total of 46 patients were enrolled. The baseline characteristics are summarized in Table 1.

145 **3.1 Efficacy**

All patients completed the treatments. Five patients did not complete the 1-month follow-up, and seven 146

patients did not complete the 3-month follow-up (Figure 1). At the post-treatment visit, 37 patients 147

medRxiv preprint doi: https://doi.org/10.1101/2024.08.01.24311339; this version posted August 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

(80.4%) achieved a response, with 27 (58.7%) achieving remission. The mean number of treatment 148 sessions was 6.0 + 2.1, with 3.0 + 1.7 sessions of ECT and 3.2 + 1.6 sessions of LCE. Forty-three 149 patients transitioned from ECT to LCE due to meeting the ECT-LCE transition criteria. Three patients 150 did not meet the criteria and remained on ECTs throughout the trial, all three were non-responders. The 151 152 reduction in MADRS score was 19.1 + 7.0, with Hedges' g = 3.29 (95% CI = 2.66 to 3.91). For details,

153 please see sFigure 1 and Table 2.

Following i-HECT treatments, significant improvements were observed across various measures 154 including MADRS, PHQ-9, GAD-7, C-SSRS, and PANSS. Notably, cognitive function, a key focus of 155 this trial, demonstrated significant improvements in both subjective and objective assessments. 156

(sFigure 2–4, and Table 2) 157

3.2 Safety 158

The most commonly reported AEs were memory complaints, headaches, and fatigue. The incidence of 159 160 these three AEs, along with nausea and dizziness, are notably lower after LCE compared to ECT, and the ORTs after LCEs were significantly shorter than ECTs (Table 3). 161

162 3.3 Data accessibility

The data that support the findings of this study are available from the corresponding author, upon 163 164 reasonable request.

165

4. Discussion 166

In brief, i-HECT showed comparable antidepressant efficacy to ECT. Moreover, the most 167 promising outcome was the significant improvement observed in both subjective and objective 168 cognitive functions post-treatment, with this trend continuing during the 3-month follow-up period. 169 Young patients with depression are typically in early stages of their education or career, making prompt 170 intervention imperative. While ECT is a most evidence-supported rapid antidepressant treatment, 171 concerns about cognitive side effects have reduced its use in this population of young patients with 172 depression. However, our i-HECT protocol may provide a new and simple option for addressing these 173 174 concerns in these young individuals.


One major advantage of i-HECT is its compatibility with existing ECT equipment worldwide, 175 176 requiring no specialized modifications. Another advantage is its simple setup, requiring no additional 177 training for operators.

In conclusion, our i-HECT protocol offers promise as a rapid antidepressant treatment for young 178 patients with depression, with the added benefit of improving cognitive function. Its simplicity makes 179 180 it a potentially valuable treatment option.

References 182

- [1] Ghaziuddin N, Kutcher SP, Knapp P, American Academy of Child and Adolescent Psychiatry Work 183 Group on Quality Issues. Summary of the practice parameter for the use of electroconvulsive therapy 184 adolescents. Child Adolesc Psychiatry 2004;43:119-22. 185 with J Am Acad https://doi.org/10.1097/00004583-200401000-00028. 186
- [2] Ghaziuddin N, Laughrin D, Giordani B. Cognitive side effects of electroconvulsive therapy in 187 adolescents. J Child Adolesc Psychopharmacol 2000;10:269-76. 188 https://doi.org/10.1089/cap.2000.10.269. 189
- [3] Zhang J, Xu S, Zeng L, Chen L, Li J, Jiang Z, et al. Improved Safety of Hybrid Electroconvulsive 190 Therapy Compared With Standard Electroconvulsive Therapy in Patients With Major Depressive 191 192 Disorder: A Randomized, Double-Blind, Parallel-Group Pilot Trial. Frontiers in Psychiatry 2022;13.
- [4] Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10. 193 194 https://doi.org/10.1016/0197-2456(89)90015-9.
- [5] World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for 195 196 medical research involving human subjects. JAMA 2013;310:2191-4. https://doi.org/10.1001/jama.2013.281053. 197
- 198 [6] Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 199 1979;134:382-9. https://doi.org/10.1192/bjp.134.4.382.
- [7] O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety 200 201 of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62:1208–16. https://doi.org/10.1016/j.biopsych.2007.01.018. 202
- [8] Kellner CH, Knapp R, Husain MM, Rasmussen K, Sampson S, Cullum M, et al. Bifrontal, bitemporal 203 and right unilateral electrode placement in ECT: randomised trial. Br J Psychiatry 2010;196:226–34. 204 https://doi.org/10.1192/bjp.bp.109.066183. 205
- [9] Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen 206 Intern Med 2001;16:606–13. https://doi.org/10.1046/j.1525-1497.2001.016009606.x. 207
- 208 [10] Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Intern Med 2006;166:1092-7. 209 Arch 210 https://doi.org/10.1001/archinte.166.10.1092.
- [11] Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide 211 Severity Rating Scale: initial validity and internal consistency findings from three multisite studies 212 with adolescents adults. Psychiatry 213 and Am J 2011;168:1266-77. https://doi.org/10.1176/appi.ajp.2011.10111704. 214
- 215 [12] Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. https://doi.org/10.1093/schbul/13.2.261. 216
- 217 [13] Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 218 1998;20:310-9. https://doi.org/10.1076/jcen.20.3.310.823. 219
- [14] Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology 220 221 1935;18:643.
- 222 [15] Kuznetsova A, Brockhoff PB, Christensen RHB. ImerTest Package: Tests in Linear Mixed Effects 223 Models. Journal of Statistical Software 2017;82:1-26. https://doi.org/10.18637/jss.v082.i13.
- 224

Figure captions



- **227** Figure 1. Flow chart. Abbreviations: ECT: electroconvulsive therapy; LCE: low-charge electrotherapy;
- 228 ST: seizure threshold; rTMS: repetitive transcranial magnetic stimulation; MADRS: Montgomery-
- 229 Åsberg Depression Rating Scale; i-HECT: individualized Hybrid-ECT.

Table 1. Baseline Characteristics.

Characteristic	Results
Sex, Female, n (%)	32 (69.6%)
Age, year, mean \pm SD	18.7 ± 2.3
Education Years, mean \pm SD	11.8 ± 1.9
Diagnosis, MDD/BPD, n (%)	27 (58.7%)/19 (41.3%)
With Psychotic Feature, n (%)	19 (41.3%)
Onset Age, year, mean \pm SD	15.8 ± 2.9
Disease Course, year, mean \pm SD	2.7 ± 1.5
Current Episode, month, mean \pm SD	3.8 ± 4.3
History of ECT, n (%)	5 (10.9%)
Equivalent Fluoxetine Dose, mg/day, mean \pm SD	46.5 ± 16.2
Equivalent Olanzapine Dose, mg/day, mean \pm SD	8.7 ± 3.8
Montgomery-Åsberg Depression Rating Scale (MADRS)	31.9 ± 5.6
Total Score, mean \pm SD	
Cognitive Pessimism, mean \pm SD	14.4 ± 2.3
Affective, mean \pm SD	9.1 ± 2.3
Cognitive Anxiety, mean \pm SD	5.1 ± 1.8
Vegetative, mean \pm SD	6.2 ± 2.0
9-item Patient Health Questionnaire (PHQ-9), mean \pm SD	19.3 ± 5.4
Generalized Anxiety Disorder 7 (GAD-7), mean \pm SD	12.1 ± 5.6
Columbia–Suicide Severity Rating Scale (C-SSRS)	
Suicidal Ideation and Attempts, mean \pm SD	3.5 ± 1.1
Intensity of Ideation, mean \pm SD	16.3 ± 4.2
Stopped Suicide Attempt, mean \pm SD	3.0 ± 1.6
Positive and Negative Syndrome Scale (PANSS)	
Positive Scale, mean \pm SD	13.0 ± 2.3
Negative Scale, mean \pm SD	17.9 ± 5.0
General Psychopathology Scale, mean \pm SD	37.1 ± 5.4
Subjective Cognitive Decline Questionnaire, mean \pm SD	14.4 ± 4.3
The Repeatable Battery for the Assessment of Neuropsychologica	l Status (RBANS)
Total Score, mean \pm SD	396.1 ± 55.6
Immediate Memory, mean \pm SD	70.8 ± 14.1
Visuospatial/Constructional, mean \pm SD	83.4 ± 13.4
Language, mean \pm SD	69.0 ± 18.5
Attention, mean \pm SD	97.0 ± 14.4
Delayed Memory, mean \pm SD	76.0 ± 19.6
Stroop Color and Word Test	
Error Interference Score, mean \pm SD	2.0 ± 1.9
Time Interference Score, second, mean \pm SD	39.1 ± 11.0

Table 2. Clinical and Cognitive Outcomes. 233

Outcomes	Visit	Change From Baseline (95% CI)	р
Montgomery-Åsberg Depression	Rating Scale (MADRS)		
Total Score	Met ECT-LCE Criteria	-13.4 (-15.4 to -11.4)	< 0.001
	Post Treatment	-19.9 (-21.8 to -18)	< 0.001
	One Month Follow Up	-14.6 (-16.6 to -12.6)	< 0.001
	Three Month Follow Up	-17.4 (-19.4 to -15.4)	< 0.001
Cognitive Pessimism	Met ECT-LCE Criteria	-6.8 (-7.8 to -5.8)	< 0.001
	Post Treatment	-9.5 (-10.5 to -8.5)	< 0.001
	One Month Follow Up	-6.9 (-7.9 to -5.9)	< 0.001
	Three Month Follow Up	-7.5 (-8.5 to -6.5)	< 0.001
Affective	Met ECT-LCE Criteria	-3.7 (-4.5 to -3)	< 0.001
	Post Treatment	-6 (-6.7 to -5.3)	< 0.001
	One Month Follow Up	-4.9 (-5.6 to -4.2)	< 0.001
	Three Month Follow Up	-5.7 (-6.5 to -5)	< 0.001
Cognitive Anxiety	Met ECT-LCE Criteria	-1.7 (-2.2 to -1.1)	< 0.001
	Post Treatment	-3.1 (-3.7 to -2.6)	< 0.001
	One Month Follow Up	-2.2 (-2.7 to -1.6)	< 0.001
	Three Month Follow Up	-2.6 (-3.2 to -2.1)	< 0.001
Vegetative	Met ECT-LCE Criteria	-2.6 (-3.3 to -2)	< 0.001
	Post Treatment	-3.3 (-3.9 to -2.7)	< 0.001
	One Month Follow Up	-2.3 (-3 to -1.7)	< 0.001
	Three Month Follow Up	-3.4 (-4.1 to -2.7)	< 0.001
9-item Patient Health Questionna	aire (PHQ-9)		
	Met ECT-LCE Criteria	-7.4 (-9.3 to -5.5)	< 0.001
	Post Treatment	-9.2 (-11.1 to -7.3)	< 0.001
	One Month Follow Up	-5 (-7 to -3.1)	< 0.001
	Three Month Follow Up	-5.9 (-7.8 to -3.9)	< 0.001
Generalized Anxiety Disorder 7 (GAD-7)		
	Met ECT-LCE Criteria	-5.3 (-7 to -3.5)	< 0.001
	Post Treatment	-6.4 (-8.1 to -4.7)	< 0.001
	One Month Follow Up	-3.5 (-5.3 to -1.8)	< 0.001
	Three Month Follow Up	-3 (-4.8 to -1.2)	0.002
Columbia–Suicide Severity Ratir	ig Scale (C-SSRS)		
Suicidal Ideation and Attempts	Post Treatment	-2.1 (-2.5 to -1.7)	< 0.001
	One Month Follow Up	-1.3 (-1.8 to -0.9)	< 0.001
	Three Month Follow Up	-1.5 (-1.9 to -1)	< 0.001
Intensity of Ideation	Post Treatment	-7.8 (-9.6 to -6)	< 0.001
	One Month Follow Up	-4.3 (-6.2 to -2.4)	< 0.001
	Three Month Follow Up	-5.6 (-7.6 to -3.7)	< 0.001
Stopped Suicide Attempt	Post Treatment	-2.3 (-2.8 to -1.8)	< 0.001
	One Month Follow Up	-1.5 (-2 to -1)	< 0.001
	Three Month Follow Up	-1.8 (-2.3 to -1.3)	< 0.001


Positive and Negative Syndrome	Scale (PANSS)		
Positive Scale	Post Treatment	-4 (-4.8 to -3.2)	< 0.001
	One Month Follow Up	-2.5 (-3.3 to -1.7)	< 0.001
	Three Month Follow Up	-3.2 (-4 to -2.4)	< 0.001
Negative Scale	Post Treatment	-6.9 (-8.2 to -5.7)	< 0.001
	One Month Follow Up	-5.3 (-6.6 to -4)	< 0.001
	Three Month Follow Up	-6.2 (-7.6 to -4.9)	< 0.001
General Psychopathology Scale	Post Treatment	-12.3 (-14 to -10.7)	< 0.001
	One Month Follow Up	-9.5 (-11.2 to -7.8)	< 0.001
	Three Month Follow Up	-10.6 (-12.3 to -8.9)	< 0.001
Subjective Cognitive Decline Que	stionnaire		
	Met ECT-LCE Criteria	-1.9 (-3.3 to -0.5)	0.007
	Post Treatment	-3.3 (-4.7 to -1.9)	< 0.001
	One Month Follow Up	-2.7 (-4.1 to -1.2)	< 0.001
	Three Month Follow Up	-3.5 (-4.9 to -2.1)	< 0.001
The Repeatable Battery for the A	ssessment of Neuropsychologi	cal Status (RBANS)	
Total Score	Met ECT-LCE Criteria	32.9 (18.9 to 47)	< 0.001
	Post Treatment	58.4 (45.3 to 71.4)	< 0.001
	One Month Follow Up	57.7 (44.1 to 71.3)	< 0.001
	Three Month Follow Up	70.5 (56.7 to 84.3)	< 0.001
Immediate Memory	Met ECT-LCE Criteria	13.7 (8.8 to 18.6)	< 0.001
	Post Treatment	23.5 (18.9 to 28)	< 0.001
	One Month Follow Up	25.5 (20.8 to 30.2)	< 0.001
	Three Month Follow Up	29 (24.2 to 33.8)	< 0.001
Visuospatial/Constructional	Met ECT-LCE Criteria	3.5 (-1.2 to 8.3)	0.145
	Post Treatment	6.3 (1.9 to 10.7)	0.006
	One Month Follow Up	2 (-2.6 to 6.6)	0.392
	Three Month Follow Up	5.2 (0.5 to 9.9)	0.03
Language	Met ECT-LCE Criteria	5.6 (1 to 10.2)	0.018
	Post Treatment	9 (4.7 to 13.3)	< 0.001
	One Month Follow Up	11.6 (7.2 to 16.1)	< 0.001
	Three Month Follow Up	11.8 (7.3 to 16.3)	< 0.001
Attention	Met ECT-LCE Criteria	3 (-1.5 to 7.5)	0.195
	Post Treatment	4.3 (0.1 to 8.5)	0.046
	One Month Follow Up	4.2 (-0.2 to 8.6)	0.061
	Three Month Follow Up	8.3 (3.8 to 12.8)	< 0.001
Delayed Memory	Met ECT-LCE Criteria	9 (4.5 to 13.5)	< 0.001
	Post Treatment	15.3 (11.1 to 19.5)	< 0.001
	One Month Follow Up	14.7 (10.3 to 19)	< 0.001
	Three Month Follow Up	16.4 (12 to 20.8)	< 0.001
Stroop Test			
Error Interference Score	Met ECT-LCE Criteria	-1.1 (-1.5 to -0.6)	< 0.001
	Post Treatment	-1.2 (-1.7 to -0.8)	< 0.001
	One Month Follow Up	-1 (-1.4 to -0.5)	< 0.001


	Three Month Follow Up	-1.4 (-1.8 to -0.9)	< 0.001
Time Interference Score	Met ECT-LCE Criteria	-4.3 (-6.9 to -1.8)	0.001
	Post Treatment	-7.3 (-9.8 to -4.8)	< 0.001
	One Month Follow Up	-2.4 (-5 to 0.2)	0.073
	Three Month Follow Up	-6.6 (-9.2 to -4)	< 0.001


236	Table 3.	Safety	Results.
-----	----------	--------	-----------------

	ECT (N = 136)	LCE $(N = 138)$	р
Adverse event (AE)			
Headache, n (%)	60 (44.1%)	21 (15.2%)	<0.001
Fatigue, n (%)	55 (40.4%)	24 (17.4%)	<0.001
Nausea, n (%)	12 (8.8%)	3 (2.2%)	0.031
Euphoria, n (%)	8 (5.9%)	7 (5.1%)	0.977
Confusion, n (%)	4 (2.9%)	3 (2.2%)	0.984
Memory Complaint, n (%)	85 (62.5%)	66 (47.8%)	0.020
Dry Mouth, n (%)	22 (16.2%)	20 (14.5%)	0.827
Muscle Pain, n (%)	17 (12.5%)	8 (5.8%)	0.086
Dizziness, n (%)	41 (30.1%)	21 (15.2%)	0.005
Irritability, n (%)	9 (6.6%)	13 (9.4%)	0.528
Orientation Recovery Test (ORT)			
Minute, Median (Q1, Q3)	24.0 (20.0 to 30.0)	19.0 (15.0 to 28.0)	<0.001


Supplementary Materials








sFigure 2. Changes in 9-item Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7 (GAD-7), and Columbia-Suicide Severity Rating Scale (C-SSRS). Note: Error bars represent 95% confidence intervals (CIs). p < 0.05, p < 0.01, p < 0.01, p < 0.001. Abbreviations: ECT: electroconvulsive therapy; LCE: low-charge electrotherapy.



sFigure 3. Changes in Positive and Negative Syndrome Scale (PANSS). Note: Error bars represent 95% confidence intervals (CIs). p < 0.05, p < 0.01, p < 0.01, p < 0.001. Abbreviations: ECT:

- electroconvulsive therapy; LCE: low-charge electrotherapy.



- sFigure 4. Changes in Objective (RBANS and Stroop tests) and Subjective Cognitive (SCDQ) 259
- **Functions.** Note: Error bars represent 95% confidence intervals (CIs). *p < 0.05, **p < 0.01, ***p < 0.01, **p < 0.01260
- 0.001. Abbreviations: RBANS: Repeatable Battery for the Assessment of Neuropsychological Status. 261
- SCDQ: Subjective Cognitive Decline Questionnaire; ECT: electroconvulsive therapy; LCE: low-charge 262
- electrotherapy. 263
- 264